AIDS Vaccine for Asia Network (AVAN): Expanding the regional role in developing HIV vaccines

PLoS Medicine

Volumn 7, Issue 9, 2010, Pages

  Kent, Stephen J ^a   Cooper, David A ^b   Vun, Mean Chhi ^c   Shao, Yiming ^d   Zhang, Linqi ^e   Ganguly, Nirmal ^f   Bela, Budiman ^g   Tamashiro, Hiko ^h   Ditangco, Rossana ⁱ   Rerks Ngarm, Supachai ^j   Pitisuttithum, Punnee ^k   van Kinh, Nguyen ^l   Bernstein, Alan ^m   Osmanov, Saladin ⁿ  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c National Center for HIV/AIDS   (Cambodia)

^d CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^e TSINGHUA UNIVERSITY   (China)

^f INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^g UNIVERSITY OF INDONESIA   (Indonesia)

^h HOKKAIDO UNIVERSITY   (Japan)

ⁱ RESEARCH INSTITUTE FOR TROPICAL MEDICINE   (Philippines)

^j MINISTRY OF PUBLIC HEALTH   (Thailand)

^k MAHIDOL UNIVERSITY   (Thailand)

^l National Institute for Infectious and Tropical Diseases   (Viet Nam)

^m Global HIV Vaccine Enterprise   (United States)

ⁿ WORLD HEALTH ORGANIZATION   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALVAC; DNA VACCINE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PEPTIDE VACCINE; UNCLASSIFIED DRUG; V3 PEPTIDE VACCINE; VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; AUSTRALIA; CHINA; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; GEOGRAPHIC DISTRIBUTION; GOOD MANUFACTURING PRACTICE; HEALTH BEHAVIOR; HEALTH PROMOTION; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; INFECTION RISK; INTRAVENOUS DRUG ABUSE; JAPAN; MALE HOMOSEXUAL; MEDICAL ETHICS; MORBIDITY; NONHUMAN; PANDEMIC; PREVALENCE; PROSTITUTION; STRATEGIC PLANNING; THAILAND; UNSAFE SEX; VACCINE PRODUCTION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS TRANSMISSION; ASIA; CLINICAL TRIAL (TOPIC); HEALTH; IMMUNOLOGY; INTERNATIONAL COOPERATION; MEDICAL RESEARCH;

AIDS VACCINES; ASIA; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; HIV INFECTIONS; HUMANS; INTERNATIONAL COOPERATION; PANDEMICS; WORLD HEALTH;

EID: 77957878683     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1000331     Document Type: Article

References (38)

1. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1881-1893.
2. Fauci AS, Johnston MI, Dieffenbach CW, Burton DR, Hammer SM, et al. (2008) HIV vaccine research: the way forward. Science 321: 530-532.
3. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. N Engl J Med 361: 2209-2220.
4. Klausner RD, Fauci AS, Corey L, Nabel GJ, Gayle H, et al. (2003) Medicine. The need for a global HIV vaccine enterprise. Science 300: 2036-2039.
5. Kaleebu P, Abimiku A, El-Halabi S, Koulla-Shiro S, Mamotte N, et al. (2008) African AIDS vaccine programme for a coordinated and collaborative vaccine development effort on the continent. PLoS Med 5: e236. doi:10.1371/journal.pmed.0050236.
6. Coordinating Committee of the Global HIV/AIDS Vaccine Enterprise (2005) The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan. PLoS Med 2: e25. doi:10.1371/journal.pmed.0020025.
7. UNAIDS (2010) Joint United Nations Programme on HIV/AIDS homepage. Available: http://www.unaids.org/en/CountryResponses/Regions/Asia.asp. Accessed 17 August 2010.
8. Marais H, editor. Commission on AIDS in Asia (2008) Redefining AIDS in Asia: crafting an effective response. Report of the Commission on AIDS in Asia. New Delhi: Oxford University Press.
9. Lu L, Jia M, Ma Y, Yang L, Chen Z, et al. (2008) The changing face of HIV in China. Nature 455: 609-611.
10. Wang W, Jiang S, Li S, Yang K, Ma L, et al. (2008) Identification of subtype B, multiple circulating recombinant forms and unique recombinants of HIV type 1 in an MSM cohort in China. AIDS Res Hum Retroviruses 24: 1245-1254.
11. Hemelaar J, Gouws E, Ghys PD, Osmanov S (2006) Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 20: W13-W23.
12. Deshpande A, Jauvin V, Pinson P, Jeannot AC, Fleury HJ (2009) Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. AIDS Res Hum Retroviruses 25: 633-635.
13. Wirachsilp P, Kantakamalakul W, Foongladda S, Chuenchitra T, Kohriangudom S, et al. (2007) Surveillance of subtype and genetic variation of the circulating strains of HIV-1 in Thailand. Southeast Asian J Trop Med Public Health 38: 814-827.
14. Pitisuttithum P (2008) HIV vaccine research in Thailand: lessons learned. Expert Rev Vaccines 7: 311-317.
15. Shao Y, Li T, Shen X, Zhang J, Zhu H, et al. (2008) The safety and immunogenicity of the replicative Tiantan vaccinia HIV vaccine in phase I clinical trial. Poster No P13-18, AIDS Vaccine 2008, Cape Town, South Africa, Oct 13-16.
16. Huang X, Lu B, Yu W, Fang Q, Liu L, et al. (2009) A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination. PLoS ONE 4: e4180. doi:10.1371/journal.pone.0004180.
17. Dai K, Liu Y, Liu M, Xu J, Huang W, et al. (2008) Pathogenicity and immunogenicity of recombinant Tiantan Vaccinia Virus with deleted C12L and A53R genes. Vaccine 26: 5062-5071.
18. Mehendale S, van Lunzen J, Clumeck N, Rockstroh J, Vets E, et al. (2008) A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine. AIDS Res Hum Retroviruses 24: 873-880.
19. Ramanathan VD, Kumar M, Mahalingam J, Sathyamoorthy P, Narayanan PR, Solomon S, et al. (2009) A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV-1 subtype C modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res Human Retroviruses 25: 1107-1116.
20. Berkley S (2008) HIV vaccine trials in India. Nat Biotechnol 26: 495. author reply 496.
21. International AIDS Vaccine Initiative (2010) Working with communities: India. Available: http://www.iavi.org/working-with-communities/country-programs/Pages/india.aspx. Accessed 17 August 2010.
22. Kelleher AD, Puls RL, Bebbington M, Boyle D, Ffrench R, et al. (2006) A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. AIDS 20: 294-297.
23. De Rose R, Fernandez CS, Smith MZ, Batten CJ, Alcantara S, et al. (2008) Control of viremia following immunotherapy of SIV-infected macaques with peptide pulsed blood. PLoS Pathog 4: e1000055. doi:10.1371/journal.ppat.1000055.
24. De Rose R, Zelikin A, Johnston APR, Sexton A, Chong SF, et al. (2008) Binding, internalisation and antigen presentation of vaccine-loaded nanoengineered capsules in blood. Advanced Materials 20: 4698-4703.
25. Stratov I, Chung A, Kent SJ (2008) Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects. J Virol 82: 5450-5459.
26. Zaunders JJ, Munier ML, Seddiki N, Pett S, Ip S, et al. (2009) High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40). J Immunol 183: 2827-2836.
27. Hiroi T, Goto H, Someya K, Yanagita M, Honda M, et al. (2001) HIV mucosal vaccine: nasal immunization with rBCG-V3J1 induces a long term V3J1 peptide-specific neutralizing immunity in Th1- and Th2-deficient conditions. J Immunol 167: 5862-5867.
28. Kawada M, Tsukamoto T, Yamamoto H, Iwamoto N, Kurihara K, et al. (2008) Gag-specific cytotoxic T-lymphocyte-based control of primary simian immunodeficiency virus replication in a vaccine trial. J Virol 82: 10199-10206.
29. Esparza J (1999) AIDS vaccine research in Asia: needs and opportunities. Report from a UNAIDS/WHO/NIID meeting Tokyo, 28-30 October 1998. AIDS 13: UNAIDS 1-UNAIDS 13.
30. Excler JL, Pitisuttithum P, Rerks-Ngarm S, Shao Y, Zhang L, et al. (2008) Expanding research capacity and accelerating AIDS vaccine development in Asia. Southeast Asian J Trop Med Public Health 39: 766-784.
31. Rerks-Ngarm S, Pitisuttithum P, Ganguly N, Zhang Li, Tamashiro H, et al. (2010) Defining the objectives of the AIDS Vaccine for Asia Network: WHO-UNAIDS/Global HIV Vaccine Enterprise regional consultation on expanding AIDS vaccine research and development capacity in Asia. Curr Opin HIV AIDS 5: 435-452.
32. Lenihan F (1993) China and Thailand to start trials of AIDS vaccines. BMJ 306: 1564-1565.
33. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, et al. (2006) Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 194: 1661-1671.
34. Thongcharoen P, Suriyanon V, Paris RM, Khamboonruang C, de Souza MS, et al. (2007) A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J Acquir Immune Defic Syndr 46: 48-55.
35. Earl PL, Cotter C, Moss B, VanCott T, Currier J, et al. (2009) Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines. Vaccine 27: 5885-5895.
36. De Rose R, Chea S, Dale CJ, Reece J, Fernandez CS, et al. (2005) Subtype AE HIV-1 DNA and recombinant Fowlpoxvirus vaccines encoding five shared HIV-1 genes: safety and T cell immunogenicity in macaques. Vaccine 23: 1949-1956.
37. Shao Y, Li T, Wolf H, Liu Y, Wang H, et al. (2009) The safety and immunogenicity of HIV-1 vaccines based on DNA and replication competent vaccinia vector in phase I clinical trial. Poster NoP14-15LB, AIDS Vaccine 2009, Paris, Oct 19-22.
38. Kumar S, Aggarwal P, Vajpayee M, Pandey RM, Seth P (2006) Development of a candidate DNA/MVA HIV-1 subtype C vaccine for India. Vaccine 24: 2585-2593.